Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VOR Vor Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: VOR
Price (delayed)
$1.06
Market cap
$132.46M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
$110.78M
Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that
Highlights
VOR's EPS is up by 15% YoY and by 11% from the previous quarter
The debt is down by 11% YoY and by 3.3% from the previous quarter
Vor Biopharma's quick ratio has plunged by 55% YoY and by 26% from the previous quarter
Vor Biopharma's equity has decreased by 46% YoY and by 32% from the previous quarter
Key stats
What are the main financial stats of VOR
Market
Valuations
Earnings
Shares outstanding
124.96M
Market cap
$132.46M
Enterprise value
$110.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
2
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$122.15M
Net income
-$118.6M
EBIT
-$118.6M
EBITDA
-$110.07M
Free cash flow
-$100.61M
Per share
Balance sheet
Liquidity
EPS
-$1.51
EPS diluted
-$1.51
Free cash flow per share
-$0.81
Book value per share
$0.53
Revenue per share
$0
TBVPS
$0.88
Total assets
$109.31M
Total liabilities
$43.24M
Debt
$30.78M
Equity
$66.07M
Working capital
$48.12M
Debt to equity
0.47
Current ratio
3.88
Quick ratio
3.73
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-93.1%
Return on equity
-142.1%
Return on invested capital
-155.5%
Return on capital employed
-128.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VOR stock price
How has the Vor Biopharma stock price performed over time
Intraday
19.1%
1 week
341.12%
1 month
510.95%
1 year
-7.02%
YTD
-4.5%
QTD
47.74%
Financial performance
How have Vor Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$122.15M
Net income
-$118.6M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 4.5% YoY
Price vs fundamentals
How does VOR's price correlate with its fundamentals
Growth
What is Vor Biopharma's growth rate over time
Valuation
What is Vor Biopharma stock price valuation
P/E
N/A
P/B
2
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VOR's EPS is up by 15% YoY and by 11% from the previous quarter
VOR's price to book (P/B) is 122% more than its last 4 quarters average of 0.9 and 25% more than its 5-year quarterly average of 1.6
Vor Biopharma's equity has decreased by 46% YoY and by 32% from the previous quarter
Efficiency
How efficient is Vor Biopharma business performance
The return on invested capital has dropped by 147% year-on-year and by 25% since the previous quarter
The company's return on equity has shrunk by 93% YoY and by 19% QoQ
The return on assets has dropped by 62% year-on-year and by 13% since the previous quarter
Dividends
What is VOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VOR.
Financial health
How did Vor Biopharma financials performed over time
Vor Biopharma's total assets is 153% more than its total liabilities
Vor Biopharma's quick ratio has plunged by 55% YoY and by 26% from the previous quarter
Vor Biopharma's current ratio has plunged by 54% YoY and by 25% from the previous quarter
The debt is 53% less than the equity
Vor Biopharma's debt to equity has surged by 68% YoY and by 42% QoQ
Vor Biopharma's equity has decreased by 46% YoY and by 32% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.